Clicky

BioCardia, Inc.(BCDA)

Description: BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.


Keywords: Biotechnology Life Sciences Biology Stem Cell Cell Therapy Catheter Cardiovascular Disease Regenerative Medicine Bone Heart Failure Vascular Disease Heart Disease Bone Marrow Aging Associated Diseases Vascular Access Products Ischemia Treatment Of Heart Failure Catheter Products

Home Page: www.biocardia.com

BCDA Technical Analysis

320 Soquel Way
Sunnyvale, CA 94085
United States
Phone: 650 226 0120


Officers

Name Title
Dr. Peter A. Altman Ph.D. CEO, Pres & Director
Mr. David McClung Chief Financial Officer
Mr. Edward M. Gillis Sr. VP of Devices
Dr. Ian McNiece Ph.D. Chief Scientific Officer
Dr. Sujith Shetty Chief Medical Officer and VP of Clinical & Regulatory

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 7.5775
Price-to-Sales TTM: 23.7668
IPO Date: 2008-03-14
Fiscal Year End: December
Full Time Employees: 28
Back to stocks